Zealand Pharma says weight loss drug could be comparable to GLP1-RAs [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The Danish biotech company has shared data showing that its investigational weight loss drug petrelintide resulted in body weight reduction in the high dose cohort of 8.6%, compared with 1.7% in the placebo arm, in the second part of a Phase Ib trial. “These data pave the way for rapid progression to Phase IIb trials of petrelintide and further support the potential of this long-acting amylin analogue to deliver weight loss comparable to GLP-1 receptor agonists with a better patient experience,” said Zealand Pharma CMO David Kendall. The company's share price rose by 23% after it shared the trial data. “We look forward to initiation of the Phase IIb clinical trial of petrelintide in people living with overweight and obesity later in 2024,” Kendall added. Zealand's trial (NCT05613387) is a single-centred, double-blind trial evaluating the safety and tolerability of multiple doses of its investigational amylin analogue petrelintide in healthy volunteers. The trial, which was
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma [Yahoo! Finance]Yahoo! Finance
- 2seventy bio completes $40m haemophilia A program deal with Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal [Yahoo! Finance]Yahoo! Finance
- Weight-loss patients warned of counterfeit Ozempic as dupes popular of drug proliferate [USA TODAY]USA TODAY
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 6/26/24 - Form 6-K
- 6/24/24 - Form 6-K
- 6/21/24 - Form 11-K
- NVO's page on the SEC website